Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14241831 | 1.00 | EPHX1 (0.57) | EPHX1NPC1RAB9ACA12CA1 | |
| SCHEMBL9967995 | 0.98 | EPHX1 (0.53) | EPHX1NPC1RAB9ACA12CA1 | |
| SCHEMBL21941874 | 0.94 | EPHX1 (0.48) | EPHX1NPC1RAB9ACA12CA1 | |
| SCHEMBL25897083 | 0.89 | SMN1; SMN2 (0.57) | EPHX1NPC1RAB9ACA12CA1 | |
| SCHEMBL256679 | 0.89 | — | — | |
| SCHEMBL9202 | 0.84 | EPHX1 (0.53) | EPHX1NPC1RAB9ACA12CA1 | |
| SCHEMBL4761356 | 0.83 | TDP1 (0.48) | EPHX1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL14094370 | 0.82 | TDP1 (0.47) | EPHX1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL19151014 | 0.82 | TDP1 (0.47) | EPHX1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL13686045 | 0.82 | TDP1 (0.47) | EPHX1NPC1RAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109400573-B | Benzo [ d ] [1,3] dioxole compound, preparation method and application thereof | 中国人民解放军第二军医大学 | 2023-04-11 | — | — | CN | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3433250-B1 | HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-11091591-B2 | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids | UNIVERSITÄT BASEL (CH) | 2021-08-17 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-03-23 | — | — | US | disclosed |
| US-20200079774-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-03-12 | — | — | US | disclosed |
| US-20190327969-A1 | HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-31 | — | — | US | disclosed |
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| WO-2009134942-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG. (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | EPHX1 3379/4885NPC1 2654/4885RAB9A 703/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | EPHX1 185/4885NPC1 1968/4885RAB9A 2417/4885 |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | CD4, CD40LG, CD14 | EPHX1 3372/4885NPC1 3968/4885RAB9A 4442/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | EPHX1 2260/4885NPC1 4008/4885RAB9A 2816/4885 |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | EPHX1 810/4885NPC1 4064/4885RAB9A 619/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | EPHX1 2260/4885NPC1 4008/4885RAB9A 2816/4885 |
| US-20200079774-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | EPHX1 810/4885NPC1 4064/4885RAB9A 619/4885 |
| US-20190327969-A1 | HERBICIDES | DDT, HPD, PDXK | EPHX1 77/4885NPC1 4863/4885RAB9A 3340/4885 |
| US-11091591-B2 | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids | SIGLEC7, GBA2, GBA1 | EPHX1 991/4885NPC1 755/4885RAB9A 1265/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | EPHX1 3379/4885NPC1 2654/4885RAB9A 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.